The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
175
Epic Medical Research
DeSoto, Texas, United States
Percent Change from Baseline in LDL-C
Time frame: Baseline, Day 90
Percent Change from Baseline in LDL-C
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline in Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline Total Cholesterol
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline in Apolipoprotein B
Time frame: Baseline to End of Study (up to Day 365)
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.